SCHILLING REDLICH, ANDREA INGRID
Thumbnail Image
Preferred name
SCHILLING REDLICH, ANDREA INGRID
Main Affiliation
Email
aschilling@udd.cl
ORCID
Scopus Author ID
7101797606

Research Output

2023 2023 2022 2022 2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 2014 2014 0.0 0.0 0.5 0.5 1.0 1.0 1.5 1.5 2.0 2.0 2.5 2.5 3.0 3.0

Filters

1
15
15
Reset filters

Settings
Now showing 1 - 10 of 15
No Thumbnail Available
Publication

Disparities in Stroke Incidence Over Time by Sex and Age in Latin America and the Caribbean Region 1997 to 2021: A Systematic Review and Meta‐Analysis

2023 , Marilaura Nuñez , Carlos Delfino , Claudia Asenjo‐Lobos , SCHILLING REDLICH, ANDREA INGRID , LAVADOS GERMAIN, PABLO MANUEL , Craig S. Anderson , MUÑOZ VENTURELLI, PAULA ANDREA

Background High‐income country studies show unfavorable trends in stroke incidence (SI) in younger populations. We aimed to estimate temporal change in SI disaggregated by age and sex in Latin America and the Caribbean region. Methods and Results A search strategy was used in MEDLINE, WOS, and LILACS databases from 1997 to 2021, including prospective population‐based observational studies with first‐ever stroke incidence in Latin America. Reports without data broken down by age and sex were excluded. Risk of bias was assessed with The Joanna Briggs Institute's guide. The main outcomes were incidence rate ratio and relative temporal trend ratio of SI, comparing time periods before 2010 with after 2010. Pooled relative temporal trend ratios considering only studies with 2 periods in the same population were calculated by random‐effects meta‐analysis. Meta‐regression analysis was used to evaluate incidence rate determinants. From 9242 records identified, 6 studies were selected including 4483 first‐ever stroke in 4 101 084 individuals. Crude incidence rate ratio in younger subjects (<55 years) comparing before 2010:after 2010 periods showed an increase in SI in the past decade (incidence rate ratio, 1.37 [95% CI, 1.23–1.50]), in contrast to a decrease in older people during the same period (incidence rate ratio, 0.83 [95% CI, 0.76–0.89]). Overall relative temporal trend ratio (<55:≥55 years) was 1.65 (95 CI%, 1.50–1.80), with higher increase in young women (pooled relative temporal trend ratio, 3.08 [95% CI, 1.18–4.97]; P for heterogeneity <0.001). Conclusions An unfavorable change in SI in young people, especially in women, was detected in population‐based studies in the past decade in Latin America and the Caribbean. Further investigation of the explanatory variables is required to ameliorate stroke prevention and inform local decision‐makers. Registration URL: https://www.crd.york.ac.uk/prospero/ Identifier: CRD42022332563.

View
No Thumbnail Available
Publication

Beneficios no anticonceptivos de 0,02 mg de etinilestradiol/2 mg de acetato de clormadinona administrados en un régimen de 24+4 días

2011 , Hans Peter Zahradnik , Aida Hanjalic-Beck , SCHILLING REDLICH, ANDREA INGRID

View
No Thumbnail Available
Publication

Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine

2021 , Jacob Bornstein , Surita Roux , Lone Kjeld Petersen , Li-Min Huang , Simon R. Dobson , Punnee Pitisuttithum , Javier Diez-Domingo , SCHILLING REDLICH, ANDREA INGRID , Hany Ariffin , Richard Tytus , Richard Rupp , Shelly Senders , Eli Engel , Daron Ferris , Yae-Jean Kim , Young Tae Kim , Zafer Kurugol , Oliver Bautista , Katrina M. Nolan , Sandhya Sankaranarayanan , Alfred Saah , Alain Luxembourg

BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9–14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16–26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%–100%; IgG-LIA: 91%–100%) and young women who received 3 doses (cLIA: 78%–98%; IgG-LIA: 91%–100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose.

View
No Thumbnail Available
Publication

Prevalence and management of condylomas in consulting population in Chile: "DIACON study" [Prevalencia y manejo de condilomas en poblacion consultante en Chile: estudio "DIACON"]

2019 , Andrea Schilling R. , Andrea Huneeus V. , Alejandra Massoc P. , Francisca Rivera M. , Gabriel Cavada Ch. , SCHILLING REDLICH, ANDREA INGRID

View
No Thumbnail Available
Publication

Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile

2023 , Nicole Le Corre , Katia Abarca , Patricio Astudillo , Marcela Potin , Sofía López , Macarena Goldsack , Vania Valenzuela , SCHILLING REDLICH, ANDREA INGRID , Victoria Gaete , Lilian Rubio , Mario Calvo , Loreto Twele , Marcela González , Daniela Fuentes , Valentina Gutiérrez , Felipe Reyes , Lorena I. Tapia , Rodolfo Villena , Angello Retamal-Díaz , Antonio Cárdenas , Eduardo Alarcón-Bustamante , Xing Meng , Qianqian Xin , José V. González-Aramundiz , María Javiera Álvarez-Figueroa , Pablo A. González , Susan M. Bueno , Jorge A. Soto , Cecilia Perret , Alexis M. Kalergis

During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.

View
No Thumbnail Available
Publication

Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial

2022 , Katia Abarca , Carolina Iturriaga , Marcela Urzúa , Nicole Le Corre , Augusto Pineda , Carolina Fernández , Angélica Domínguez , CEA GONZALEZ, PABLO ANTONIO , Susan M. Bueno , Paulina Donato , Pilar Espinoza , Daniela Fuentes , Marcela González , Paula Guzmán , MUÑOZ VENTURELLI, PAULA ANDREA , Carlos M. Pérez , Marcela Potin , Álvaro Rojas , José V. González-Aramundiz , Nicolás M. S. Gálvez , Francisca Aguirre-Boza , Sofía Aljaro , Luis Federico Bátiz , Yessica Campisto , Mariela Cepeda , Aarón Cortés , Sofía López , María Loreto Pérez , SCHILLING REDLICH, ANDREA INGRID , Alexis M. Kalergis

Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe COVID-19 cases. We investigate the safety and non-inferiority of two immunization schedules of CoronaVac® in a non-inferiority trial in healthy adults. A total of 2302 healthy adults were enrolled at 8 centers in Chile and randomly assigned to two vaccination schedules, receiving two doses with either 14 or 28 days between each. The primary safety and efficacy endpoints were solicited adverse events (AEs) within 7 days of each dose, and comparing the number of cases of SARS-CoV-2 infection 14 days after the second dose between the schedules, respectively. The most frequent local AE was pain at the injection site, which was less frequent in participants aged ≥60 years. Other local AEs were reported in less than 5% of participants. The most frequent systemic AEs were headache, fatigue, and myalgia. Most AEs were mild and transient. There were no significant differences for local and systemic AEs between schedules. A total of 58 COVID-19 cases were confirmed, and all but 2 of them were mild. No differences were observed in the proportion of COVID-19 cases between schedules. CoronaVac® is safe, especially in ≥60-year-old participants. Both schedules protected against COVID-19 hospitalization.

View
No Thumbnail Available
Publication

Frequently asked questions regarding the human papillomavirus vaccines [Preguntas frecuentes respecto a la vacuna contra el virus papiloma humano]

2018 , SCHILLING REDLICH, ANDREA INGRID

View
No Thumbnail Available
Publication

Cervical Artery Dissection in Postpartum Women after Cesarean and Vaginal Delivery

2022 , Francisca Urrutia , MAZZON AGURTO, ENRICO , BRUNSER, ALEJANDRO , DIAZ TAPIA, VIOLETA DEL CARMEN , CALDERON GIADROSIC, JUAN FRANCISCO , STECHER GUZMAN, XIMENA PATRICIA , Tomas Bernstein , Paulo Zuñiga , SCHILLING REDLICH, ANDREA INGRID , MUÑOZ VENTURELLI, PAULA

View
No Thumbnail Available
Publication

Criterios Médicos de elegibilidad para el uso de anticonceptivos de la OMS

2017 , Daniela Capella S , Andrea Schilling R , Claudio Villaroel Q

View
No Thumbnail Available
Publication

Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

2022 , Jorge A. Soto , Felipe Melo-González , Cristián Gutierrez-Vera , Bárbara M. Schultz , Roslye V. Berríos-Rojas , Daniela Rivera-Pérez , Alejandro Piña-Iturbe , Guillermo Hoppe-Elsholz , Luisa F. Duarte , Yaneisi Vázquez , Daniela Moreno-Tapia , Mariana Ríos , Pablo A. Palacios , Richard Garcia-Betancourt , Álvaro Santibañez , Gaspar A. Pacheco , Constanza Mendez , Catalina A. Andrade , Pedro H. Silva , Benjamín Diethelm-Varela , Patricio Astudillo , Mario Calvo , Antonio Cárdenas , Marcela González , Macarena Goldsack , Valentina Gutiérrez , Marcela Potin , SCHILLING REDLICH, ANDREA INGRID , Lorena I. Tapia , Loreto Twele , Rodolfo Villena , Alba Grifoni , Alessandro Sette , Daniela Weiskopf , Rodrigo A. Fasce , Jorge Fernández , Judith Mora , Eugenio Ramírez , Aracelly Gaete-Argel , Mónica L. Acevedo , Fernando Valiente-Echeverría , Ricardo Soto-Rifo , Angello Retamal-Díaz , Nathalia Muñoz-Jofré , Xing Meng , Qianqian Xin , Eduardo Alarcón-Bustamante , José V. González-Aramundiz , Nicole Le Corre , María Javiera Álvarez-Figueroa , CEA GONZALEZ, PABLO ANTONIO , Katia Abarca , Cecilia Perret , Leandro J. Carreño , Susan M. Bueno , Alexis M. Kalergis , Patricio Astudillo Paredes , Epifanía Hernández Jara , Héctor Morán Fernández , Javiera Arenas Urra , Stephani Ascui Baeza , María Olivia Cabrera , José Romero Muñoz , Gonzalo Alarcón Andrade , Rocío Rodríguez Espósito , Anwar Gutiérrez Silva , Fernanda Pérez Gutiérrez , Alma Muñoz Muñoz , Marcela Potin Santander , Sofia López , Tania Weil , Macarena Goldsack , Deidyland Arenas , Javiera Moore , ARAYA CASTRO, PAULINA ANDREA , Lorena Pilicita , Vania Valenzuela , Catalina Campos , Mauricio Soto , SCHILLING REDLICH, ANDREA INGRID , Alberto Trautmann , Ana Fritis , Daniela Pavez , Javiera Arancibia , Lilian Rubio , Paula Viviani , Vinka Basic , Cassandra Cárcamo , Mario Calvo Gil , Marisol Wenzel , Nicole Carey , Roberto Burgos , Loreto Twele , Daniel Beltrán , Silvana Grandón , Carlos Tovar , Marcela González , Daniela Fuentes , Teresa Ramírez , Mariela Cepeda Corrales , Nataly Martínez López , Valentina Gutiérrez , Felipe Reyes , Armando Lavayen , Melissa González , Monserrat Gutiérrez , Noris Rengifo , Carla Ortega , Florencia Saver , Lorena Tapia , Mirta Acuña , Javiera Albornoz , Tania Cariqueo , Alejandro Velásquez , Yennybeth Leiva Chamorro , Rodolfo Villena , Paola Flores , Francisca Bartsch , Belén Sepúlveda , Daniela Garmendia , Antonio Cárdenas , Angello Retamal , Carmen Ludeña , Lorena González , Carolina Hermosilla , Gustavo Keilhold , Francisco Cammarata-Scalisi , Jessica Álvarez , Jessica Romero , Pía Villarroel , Francisca Muñoz , Jorge Maya , Andrés Canales , Margarita K. Lay , Christian Muñoz , Roylester Araya , Kanta Subbarao

This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population.

View